---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-26-000035"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2026-07-30T20:02:28+00:00"
generated_at: "2026-07-30T20:03:07.424863+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q2 revenue $959M (+39% YoY); raises INGREZZA guidance to $2.825-2.875B

## Summary
- GAAP EPS $1.39 vs $1.06 YoY; Non-GAAP EPS $2.85 vs $1.65 YoY.
- INGREZZA net sales $716M (+15% YoY); full-year guidance raised from $2.7-2.8B to $2.825-2.875B.
- CRENESSITY sales $184M (+247% YoY); VYKAT XR contributed $54M from May 18 acquisition close.
- Acquired Soleno Therapeutics for $53/share ($2.9B equity value) in May; added VYKAT XR for Prader-Willi syndrome.
- Entered $1.0B revolving credit facility; cash & securities $482M (down from $2.543B at year-end due to acquisition).

## SEC filing metadata
- accession: 0000914475-26-000035
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2026-07-30T20:02:28+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/0000914475-26-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/nbix-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-26-000035
- JSON: https://secwatch.observer/filing/0000914475-26-000035.json
- Plain text: https://secwatch.observer/filing/0000914475-26-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.